Research
Hormonal
The evolution of anti-obesity pharmacotherapy has progressed to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.
Practitioners should consider GLP-1RAs as effective options for appetite control and glycemic management in obesity treatment.
StrongSupportsmedium confidence
The evolution of anti-obesity pharmacotherapy has progressed from the use of high-risk agents such as amphetamines and thyroid extracts to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.
Why this rating
The claim is based on a review of existing pharmacotherapy literature.
Source
Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Xingrong Feng et al. · Chinese Medical Journal · 2025
reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →